Literature DB >> 12469159

Expression of cyclin D1 but not of cyclin E is an indicator of poor prognosis in small adenocarcinomas of the lung.

Mizuki Ikehara1, Fumihiro Oshita, Hiroyuki Ito, Naoki Ohgane, Rie Suzuki, Haruhiro Saito, Kouzo Yamada, Kazumasa Noda, Aki Mitsuda, Yoichi Kameda.   

Abstract

We investigated the significance of cyclin D1 and cyclin E expression in resected tumors on the survival of patients with small adenocarcinomas of the lung. Seventy-two patients with resected tumors <2 cm in diameter and of pathological stage I were entered into the study. There were 29 males and 43 females, with a median age of 64 years (range 26-83 years). The patients underwent curative surgical resection for lung cancer between July 1992 and November 1999. The resected tumors were subjected to immunostaining for cyclin D1 and cyclin E expression. Twenty-six patients had tumors with >20% cyclin D1-positive cells, but only 1 patient had a tumor with >20% cyclin E-positive cells. When the survival of 72 patients was compared in relation to their oncogene expression, the overall survival of patients with positive expression of cyclin D1 was significantly worse than that of individuals whose tumors had negative expression of the gene (log-rank test p=0.0049). Increased expression of cyclin D1 but not of cyclin E is an indicator of poor prognosis in patients with small adenocarcinomas of the lung.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12469159

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

Review 1.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

2.  Prognostic value of cyclin D1 overexpression in correlation with pRb and p53 status in non-small cell lung cancer (NSCLC).

Authors:  Dorota Dworakowska; Ewa Jassem; Jacek Jassem; Carsten Boltze; Klaus Hermann Wiedorn; Rafał Dworakowski; Jan Skokowski; Kazimierz Jaśkiewicz; Eugenia Czestochowska
Journal:  J Cancer Res Clin Oncol       Date:  2005-04-05       Impact factor: 4.553

Review 3.  Prognostic markers in lung cancer: is it ready for prime time?

Authors:  Chang-Qi Zhu; Ming-Sound Tsao
Journal:  Transl Lung Cancer Res       Date:  2014-06

4.  Zinc protoporphyrin regulates cyclin D1 expression independent of heme oxygenase inhibition.

Authors:  Ping La; Amal P Fernando; Zhi Wang; Ameen Salahudeen; Guang Yang; Qing Lin; Clyde J Wright; Phyllis A Dennery
Journal:  J Biol Chem       Date:  2009-10-22       Impact factor: 5.157

5.  The effect of miR-338-3p on HBx deletion-mutant (HBx-d382) mediated liver-cell proliferation through CyclinD1 regulation.

Authors:  Xiaoyu Fu; Deming Tan; Zhouhua Hou; Zhiliang Hu; Guozhen Liu; Yi Ouyang; Fei Liu
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

6.  Impact of the Activation Status of the Akt/mTOR Signalling Pathway on the Clinical Behaviour of Synovial Sarcoma: Retrospective Analysis of 174 Patients at a Single Institution.

Authors:  Ying-Xue Li; Shan-Shan Ding; Wen-Juan Wen; Lin Han; Hong-Qun Wang; Huai-Yin Shi
Journal:  Cancer Manag Res       Date:  2020-03-09       Impact factor: 3.989

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.